VCM
APGE

Versant Capital Management’s Apogee Therapeutics APGE Stock Holding History

Versant Capital Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.9K Buy
240
+11
+5% +$991 ﹤0.01% 1681
2026
Q1 		$19.3K Hold
229
– – ﹤0.01% 1841
2025
Q4 		$17.3K Hold
229
– – ﹤0.01% 1730
2025
Q3 		$9.1K Hold
229
– – ﹤0.01% 1974
2025
Q2 		$9.95K Sell
229
-205
-47% -$7.8K ﹤0.01% 1892
2025
Q1 		$16.2K Buy
+434
New +$16.8K ﹤0.01% 1464

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Versant Capital Management's APGE Position: Q2 2026 in Review

Versant Capital Management increased its Apogee Therapeutics (APGE) stake by 4.8% in Q2 2026, buying an estimated $991 and bringing the position to 240 shares worth $31.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1681.

Versant Capital Management first reported a position in APGE in Q1 2025 and has held it in 6 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Versant Capital Management held 240 shares of Apogee Therapeutics worth $31.9K as of Q2 2026.
  • Versant Capital Management bought 11 Apogee Therapeutics shares in Q2 2026, an estimated $991.
  • Apogee Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #1681 holding.
  • Versant Capital Management first reported a position in Apogee Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.